The company has strategically evolved its pipeline and discovery efforts to focus on the advancement of its leading in vivo therapeutics including the MGX-001 program in hemophilia A, other secreted protein disorders leveraging the MGX-001 approach, and cardiometabolic indications in collaboration with Ionis. In line with this strategic focus, the company deprioritized early discovery and platform research and reduced its workforce by 25%. As a result of these actions and its revised capital allocation strategy, the company expects to extend its cash runway into the fourth quarter of 2027.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGX:
- MGX Upcoming Earnings Report: What to Expect?
- Video: This stock is dragging down the in vivo gene editing therapy space
- Intellia Therapeutics price target lowered to $25 from $30 at H.C. Wainwright
- Amazon’s (AMZN) Alexa Chips are More Powerful than Nvidia in Fighting Disease, Says Biotech
- Metagenomi Regains Control After Affini-T Agreement Termination